Is Tesamorelin Legal in Australia?

The short answer

Tesamorelin is not approved by the Therapeutic Goods Administration (TGA) and does not appear on the Australian Register of Therapeutic Goods (ARTG) as a registered medicine for general supply. As a growth-hormone-releasing hormone (GHRH) analogue, it falls within the prescription-medicine class and is treated as a Schedule 4 substance under the Poisons Standard, meaning any legitimate therapeutic access would sit under a doctor's control, not over the counter.

Within the research-supply context, tesamorelin is handled strictly as a research-use-only laboratory compound. That means it is intended for in-vitro and laboratory research by qualified parties only, and is not supplied for human or animal use, diagnosis, treatment or any personal-health purpose. The remainder of this guide explains the regulatory framework behind that position in neutral terms.

What tesamorelin is

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, sometimes described in the literature as a growth-hormone-releasing factor (GRF) analogue. In biochemical terms, it is a peptide that binds the GHRH receptor and is studied for its role in signalling the pituitary to release endogenous growth hormone.

This mechanism places tesamorelin in the broader family of growth-hormone secretagogues and GHRH analogues, a class that attracts prescription-level regulatory handling in most jurisdictions. Describing this mechanism here is purely for research context and is not a statement about any effect in a person.

• Class: GHRH analogue (growth-hormone-releasing factor analogue)
• Nature: synthetic peptide studied in laboratory settings
• Receptor target discussed in the literature: the GHRH receptor
• Regulatory family: growth-hormone secretagogues / GHRH analogues

Its overseas regulatory status

Internationally, tesamorelin has a defined regulatory history. In the United States, the Food and Drug Administration (FDA) approved tesamorelin, marketed under the brand name Egrifta (with later formulations including Egrifta SV and Egrifta WR), with an initial approval dated 10 November 2010.

The approved United States indication is narrow and specific: it relates to the reduction of excess abdominal fat in adults living with HIV who have lipodystrophy. This is reported here solely as a regulatory fact about an overseas approval. It is not a claim about what any research-grade material does, and it is not a suggestion that any reader should use tesamorelin for that or any other purpose. An approval in one country does not carry across to Australia, where the TGA conducts its own independent assessment before any product is registered.

The TGA framework in Australia

In Australia, therapeutic goods are regulated under the Therapeutic Goods Act 1989, administered by the TGA. Before a medicine can be lawfully marketed and supplied as a therapeutic good, it generally must be entered on the ARTG following an evaluation of quality, safety and, where relevant, efficacy.

The ARTG is the central public register of goods that have passed this process. A compound that does not appear on the ARTG has not been through that registration pathway for general supply, which is the current situation for tesamorelin. Access to unapproved therapeutic goods in Australia is tightly controlled and sits with medical practitioners through specific regulatory schemes, not through open retail.

TGA and research peptides explained

Scheduling under the Poisons Standard

Separate from ARTG registration, substances in Australia are classified for access control under the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). The schedule a substance sits in determines how it may be supplied and what level of oversight applies.

GHRH analogues such as tesamorelin are treated within the Schedule 4 (Prescription Only Medicine) framework. Schedule 4 substances are those that, in a therapeutic context, require a prescription from an authorised health practitioner. This scheduling exists independently of whether a specific branded product is registered on the ARTG, and it is one reason tesamorelin cannot be treated as a general consumer product.

• Poisons Standard = SUSMP, the national scheduling system
• Schedule 4 = Prescription Only Medicine
• Scheduling controls access; ARTG controls market registration
• The two systems operate in parallel

WADA and anti-doping status

For anyone involved in sport, the World Anti-Doping Agency (WADA) maintains a Prohibited List that is relevant here. Growth-hormone-releasing factors and their analogues, along with growth-hormone secretagogues more broadly, fall within the peptide-hormones and growth-factors category (class S2) of the Prohibited List.

Substances in this category are prohibited at all times, both in and out of competition. This is noted neutrally as a compliance fact for athletes and support personnel who may encounter the name tesamorelin. The WADA list is updated periodically, so anyone bound by anti-doping rules should always check the current edition directly.

Research-use-only handling and buyer due diligence

Given the regulatory position above, tesamorelin circulating in the Australian research-supply market is handled as a research-use-only laboratory compound. It is not food, not a therapeutic good registered for supply, and not sold for human or animal consumption. Responsible suppliers label and document material accordingly and restrict it to qualified research contexts.

Buyers operating in a research capacity should apply genuine due diligence before any purchase. The research-peptide space has limited consumer protections of its own, so verification falls heavily on the purchaser. Clear documentation and honest labelling are baseline expectations, not optional extras.

• Confirm the material is described and labelled as research-use-only
• Look for batch-specific certificates of analysis and purity data
• Check that the supplier makes no therapeutic or personal-use claims
• Be wary of any listing promising health outcomes, which is a red flag
• Keep records of what was supplied and how it was represented

How to spot fake research peptides ACCC rules for research peptides in Australia

How tesamorelin compares with related peptides

Tesamorelin is often discussed alongside other growth-hormone-related research peptides, which share a similar regulatory logic in Australia. Compounds in the GHRH-analogue and secretagogue families are generally treated within the prescription-medicine framework and are not freely available registered products.

If you are researching this category, the regulatory status of neighbouring compounds follows a comparable pattern, and reviewing them can help build an accurate picture of how the TGA and Poisons Standard treat the class as a whole.

Is CJC-1295 legal in Australia? Is ipamorelin legal in Australia?